<DOC>
	<DOCNO>NCT01989143</DOCNO>
	<brief_summary>This single multiple ascend dose study first human assessment PF-06480605 . The goal study safety , tolerability , pharmacokinetics pharmacodynamics .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Intravenous Multiple Subcutaneous Intravenous Doses PF-06480605 Healthy Subjects .</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject non childbearing potential age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Female subject non childbearing potential must meet least one follow criterion : 1 . Achieved postmenopausal status , define : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; serum follicle stimulate hormone ( FSH ) level within laboratory 's reference range postmenopausal female ; 2 . Have undergone document hysterectomy and/or bilateral oophorectomy ; 3 . Have medically confirm ovarian failure . All female subject ( include female tubal ligation females NOT documented hysterectomy , bilateral oophorectomy and/or ovarian failure ) consider childbearing potential . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject ( legal representative ) inform pertinent aspect study . Xray evidence current , active TB previous inactive TB , general infection , heart failure , malignancy , clinically significant abnormality take Screening within 3 month prior Day 1 read qualify radiologist . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subjects history current positive result follow serological test : Hepatitis B surface antigen ( HBsAg ) , Hepatitis B core antibody ( HBcAb ) , anti Hepatitis C antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) . Subjects history autoimmune disorder . Subjects history allergic anaphylactic reaction therapeutic drug . History tuberculosis active , latent inadequately treated tuberculosis infection . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 half live 180 day biologics precede first dose study medication . Pregnant female ; breastfeed female ; female childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Dose escalate</keyword>
	<keyword>Single Multiple dos</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>PK/PD</keyword>
	<keyword>PF-06480605</keyword>
</DOC>